EUCTR2009-017063-42-RO进行中（未招募）1 期
Biomarkers Impact On the response to Treatment with Erlotinib in first line non-small cell lung Cancer with EGFR activating mutations - BIOTEC
Roche Romania SR0 个研究点开始时间: 2016年12月6日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Written informed consent (informed consent document to be approved by the National Ethics Committee and consent obtained prior to any study-specific procedure) for biomarkers testing and drug administration
- •2.Able to comply with the protocol
- •3.Age = 18 years
- •4.Histological documented adenocarcinoma, locally advanced - stage IIIb, metastatic - stage IV or recurrent non-squamous NSCLC.
- •5.Eastern Cooperative Oncology Group PS status 0-1
- •6.Life expectancy = 12 weeks
- •7.Patients must have evidence of disease with at least one measurable disease evaluate on RECIST criteria
- •8.Adequate haematological function:
- •a.Absolute neutrophil count (ANC) =1.5 x 109/L AND
- •b.Platelet count =100 x 109/L AND
- •c.Haemoglobin =9 g/dL (may be transfused to maintain or exceed this level)
- •9.Adequate liver function:
- •d.Total bilirubin <1.5 x upper limit of normal (ULN) AND
- •e.Asparagine aminotransferase (AST), alanine aminotransferase (ALT) <2.5 x ULN in patients without liver metastases; <5 x ULN in patients with liver metastases
- •10.Normal Serum calcium
- •11.Female and male patients with reproductive potential must use effective contraception.
- •12.If female, should not be pregnant or breast-feeding. Women with an intact uterus (unless amenorrhoeic for the last 24 months) must have a negative serum pregnancy test within 28 days prior to enrolment into the study. If a serum pregnancy test is not performed within 7 days prior to the first dose of erlotinib, a confirmatory urine test (within 72 hours prior to the first dose of erlotinib) is required.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 15
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •1.Inability or unwillingness to provide informed consent
- •2.Squamous non-small cell or small cell tumors or absence of histological report
- •3.Neoadjuvant/adjuvant chemotherapy within 6 months prior to enrolment
- •4.Prior exposure to agents directed at the HER axis (e.g. gefitinib, cetuximab, trastuzumab).
- •5.Prior chemotherapy or treatment with another systemic anti-cancer agent (for example monoclonal antibody, tyrosine kinase inhibitor) for the treatment of the patient’s current stage of disease (stage IIIB with pleural or pericardial effusion, stage IV or recurrent disease). NOTE: prior surgery and irradiation is permitted provided that the criteria outlined in the protocol for both treatments are met.
- •6.Radical radiotherapy with curative intent within 28 days prior to enrolment. Palliative radiotherapy for relief of bone pain not involving the thoracic region is allowed prior to enrolment.
- •7.Treatment with any other investigational agent, or participation in another clinical trial within 28 days prior to enrolment
- •8.Any active, non-controlled systemic disease (including infection, grade 4 hypertension, unstable angina, congestive heart failure, hepatic, renal or metabolic disease).
- •9.Clinically significant (i.e. active) cardiovascular disease for example CVA (=6 months before enrolment), myocardial infarction (=6 months before enrolment), unstable angina, congestive heart failure NYHA Class =II, serious cardiac arrhythmia requiring medication during the study and might interfere with regularity of the study treatment, or not controlled by medication
- •10.Evidence of ongoing or active infection, any other disease, neurological or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment-related complications
- •11.History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months of enrolment
- •12.Malignancies other than NSCLC within 5 years prior to randomization, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, DCIS treated surgically with curative intent
- •13.Serum creatinine > 1.5 ULN and/or creatinine clearance < 60 mL/min.
- •14.Patients are excluded if they have brain metastasis or spinal cord compression that has not yet been definitively treated with surgery and/or radiation; previously diagnosed and treated CNS metastases or spinal cord compression without evidence of stable disease (clinically stable imaging) for at least 2 months will also cause patients to be excluded.
- •15.Women with an intact uterus (unless amenorrhoeic for the last 24 months) not using effective means of contraception (oral contraceptives in case not contraindicated for use with concomitant treatment, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgically sterile) during the study and for a period of 6 months following the last administration of erlotinib. Men who do not agree to use effective contraception during the study and for a period of 90 days following the last administration of erlotinib.
- •16.Known hypersensitivity to erlotinib or any of its excipients, and any of the chemotherapies
- •17.Patients who cannot take oral medication, who require intra
研究者
相似试验
已完成
不适用
Early clinical and biomarker responses after treatment in patients with non-segmental vitiligoVitiligo10035023NL-OMON48618Academisch Medisch Centrum36
已完成
不适用
biomarker study of the effect and adverse event for neoadjuvantchemotherapy with breast cancer patinetsbreast cancerJPRN-UMIN000002324national cancer center180
已完成
4 期
A non-interventional biomarker study in patients with NSCLC of adenocarcinoma tumour histology eligible for treatment with Vargatef according to the approved labelNon small-cell lung carcinoma10029107lung cancerNL-OMON46049Boehringer Ingelheim34
招募中
2 期
A study of biomarkers that predict efficacy of or resistance to trastuzumab emtansine for patients with HER2-positive non-small cell lung cancerHER2-positive, recurrent, non-small cell lung cancerJPRN-UMIN000019446Okayama University30
进行中（未招募）
1 期
The value of blood measurements, ultrasound an muscle electric studies to fortell the outcome of low back pain and sciatic pain and to evaluate the effect of the muscle relaxant tolperisoEUCTR2019-001885-14-HUational Research, Development and Innovation Office150